The law firm ROWAN LEGAL acted as legal advisor in the successful completion of another investment round for the biotechnology company CasInvent Pharma. This strategic investment will enable the initiation of clinical development for innovative CK1 inhibitors, which represent a new direction in the treatment of resistant cancer diseases.
The investment confirms the growing trust of investors in top-notch biotechnological research conducted in the South Moravian Region and significantly strengthens the mission of CasInvent Pharma.
Find out more in the press release here. Or read more about this project on the CasInvent Pharma website.
